PIK3CD and breast cancer: The in vitro studies described above suggested that a combination of fulvestrant and a PI3K pathway inhibitor may be an effective approach for aromatase-inhibitor-resistant advanced breast cancer, particularly in PI3KCA mutant cases that are persistently ER-positive at relapse.